2020 ASCO mRCC Highlights: Does the Updated KEYNOTE-426 Analysis Support Pembrolizumab + Axitinib Superiority Over Sunitinib? Does Tumor Shrinkage Correlate With OS?

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

2020 ASCO mRCC Highlights: Does the Updated KEYNOTE-426 Analysis Support Pembrolizumab + Axitinib Superiority Over Sunitinib? Does Tumor Shrinkage Correlate With OS?

By 2020 ASCO Virtual Direct™ Highlights FEATURING Manojkumar Bupathi

48 views

August 6, 2020

0 Comments

Primary Analysis and Follow-up Data of a Combination Therapy in 1L a…

Feat. S. Ratnam

All Things PSA

Feat. J. Hamilton, M. Fabrizio, M. Taha

SIR 2023: Renal Cell Carcinoma Guidelines - What's New in 2023?

Feat. N. Kothary

16:05

Insights from 2024 ASCO® GU Annual Meeting

Recent GU Developments and Their Clinical Implications

Feat. T. Powles, B. Rini

15:58

Total Health

Best of Bladder Cancer and RCC From ESMO 2023 and GU ASCO 2024

Feat. M. Reimers

07:27

Jason Levy

Opus One: Final Results - RFA in Axial Skeleton

19:41

Balazs Halmos

How I Manage Immune Adverse Events in Solid Tumors

07:10

Viktor Grünwald

Updated Results From the CLEAR Trial: Outcomes of the Combination of…

16:19

OncoAlert

Year in Review: RCC Practice Changing and Practice Informing Trials …

Feat. T. Choueiri

09:12

Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Cabozantinib, Nivolumab, and Ipilimumab f…

Feat. B. McGregor

15:17

ASCO GU 2023 Conference Coverage

ASCO GU 2023 Systemic Therapy for Recurrent Metastatic RCC: Beyond S…

Feat. T. Zhang

15:44

Matthew Campbell

How to Select Frontline Therapy for Metastatic Clear Cell RCC

09:35

Insights from 2023 ESMO Annual Meeting

ESMO 2023 Insights: "State-of-the-Art in Adjuvant Treatment of …

Feat. G. de Velasco

23:16

Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Optimizing Therapy Selection for Patients…

Feat. B. McGregor

10:27

Robert McBane

2023 ISTH Insights: "The EVE Trial - Extending VTE Secondary Pr…

09:03

Insights from 2024 ASCO® GU Annual Meeting

ASCO® GU 2024 Insights: "Long-Term Follow-Up Data From the Chec…

Feat. D. McDermott

15:50

Pavlos Msaouel

First-Line Treatment Options in Advanced RCC: How to Choose

13:22

OncoAlert

Urology Year in Review: Prostate Cancer Screening, EMBARK Trial, PSM…

Feat. A. Merseburger

19:42

International Urology Cancer Summit - IUCS

How to Choose 1L Therapy for mRCC

Feat. M. Pal

52:18

The France Foundation

Immune Checkpoint Inhibitors & RCC: Where Are We Now?

Feat. P. Barata, T. Zhang, K. Virdee

02:52

University of Colorado Department of Medicine

Cardiotoxicity in RCC – Case Discussion

Feat. L. Kondapalli

20:23

Aly-Khan A. Lalani

Login

Login

Join VuMedi

2020 ASCO mRCC Highlights: Does the Updated KEYNOTE-426 Analysis Support Pembrolizumab + Axitinib Superiority Over Sunitinib? Does Tumor Shrinkage Correlate With OS?

Related Content